Zhi Tong Cai Jing·2026-02-04 10:08Core Viewpoint - Shanghai Pharmaceuticals has received approval from the National Medical Products Administration for the production of Sitagliptin Metformin Extended-Release Tablets, which are intended for adult patients with type 2 diabetes undergoing combined treatment [1] Group 1: Product Approval - The product is approved for production under registration certificate number 2026S00307 [1] - The drug was originally developed by Merck Sharp & Dohme and was launched in the United States in 2012 [1] - The application for registration was submitted to the National Medical Products Administration in June 2024 and was accepted [1] Group 2: Financial Investment - The company has invested approximately RMB 8.49 million in the research and development of this drug [1] Group 3: Market Impact - The approval of this generic drug will receive greater support in areas such as medical insurance payment and procurement by medical institutions, according to national policies [1] - The approval is expected to help expand the market share of the drug and enhance market competitiveness [1] - The experience gained from this approval will be valuable for the company's future generic drug applications [1]